Literature DB >> 138560

Minocycline therapy in acne vulgaris.

S I Cullen, R H Cohan.   

Abstract

A double-blind, random distribution study showed that a lower than recommended dose of minocycline--50 mg twice daily--was as effective as a dose of 250 mg twice daily of tetracycline for treatment of acne vulgaris in comparable patient groups, and that minocycline produced no vestibular side effects at the lower dosage. Like tetracycline, minocycline did not produce the phototoxicity associated with demeclocycline or the life-threatening colitis associated with clindamycin. Patients in this study did not develop a resistance either to minocycline or to tetracycline. Studies of the use of minocycline in patients who have developed tetracycline resistance and long-range studies of patients on the new lower dose of minocycline are now underway.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 138560

Source DB:  PubMed          Journal:  Cutis        ISSN: 0011-4162


  5 in total

Review 1.  Pharmacological therapies for Angelman syndrome.

Authors:  Wen-Hann Tan; Lynne M Bird
Journal:  Wien Med Wochenschr       Date:  2016-01-12

Review 2.  Acneiform facial eruptions: a problem for young women.

Authors:  Melody J Cheung; Muba Taher; Gilles J Lauzon
Journal:  Can Fam Physician       Date:  2005-04       Impact factor: 3.275

3.  Evidence based general practice: a retrospective study of interventions in one training practice.

Authors:  P Gill; A C Dowell; R D Neal; N Smith; P Heywood; A E Wilson
Journal:  BMJ       Date:  1996-03-30

Review 4.  Minocycline for acne vulgaris: efficacy and safety.

Authors:  Sarah E Garner; Anne Eady; Cathy Bennett; John Norman Newton; Karen Thomas; Catalin Mihai Popescu
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

5.  Opinion: An Existing Drug to Assess In Vivo for Potential Adjunctive Therapy of Ebola Virus Disease and Post-Ebola Syndrome.

Authors:  Katherine Hendricks; Meredith Gilman Parrado; John Bradley
Journal:  Front Pharmacol       Date:  2020-01-30       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.